Positioned to Accelerate Downgrading of Cannabinoid Medicine Scheduling.

MONTEREY, Calif., December 19, 2025 — BRC Therapeutics (BRC), a pharmaceutical
company developing proprietary therapeutics for neurological and inflammatory
diseases, celebrates yesterday’s landmark executive order that would remove cannabis
from a group of drugs classified as more dangerous than others, the so-called Schedule
I drugs under the Controlled Substances Act. Cannabis’ classification would become a
Schedule III drug.

This major shift at the federal level would move drug policy closer to what 40 states have
already implemented and underscores the therapeutic potential of cannabis‑derived
compounds or cannabinoids. The order is expected to accelerate a process that was
initiated several years ago and would greatly facilitate the development and
commercialization of cannabinoid medicines.

BRC is already operating in a federally compliant framework under stringent oversight of
the Drug Enforcement Agency (DEA), holding all required DEA licenses for research
activities and production under cGMP. This transformative policy change would add
momentum to the company’s quest to fill high unmet medical needs using botanically
derived cannabinoid therapeutics.

“Reclassification of cannabis at the federal level represents a watershed moment for
science, medicine, and the millions of patients waiting for meaningful new treatment
options,” said George Hodgin, CEO and Founder of BRC Therapeutics. “For years, the
Schedule I classification impeded research and innovation. Yesterday’s order bears the
promise that a major barrier will be lifted soon.”

BRC’s pipeline includes two investigational products that are currently being tested in
clinical trials for Complex Regional Pain Syndrome (CRPS) and Aromatase Inhibitor-
Induced Arthralgia (AIIA), respectively. A regulatory shift prompted by the order would
allow for accelerated development and increased scale.

“We believe that a rescheduling would further catalyze rigorous scientific inquiry and set
the stage for a generation of non‑addictive, evidence‑based treatments for pain and
other conditions where cannabinoids have clear therapeutic promise,” Hodgin added.

About BRC Therapeutics
BRC Therapeutics (BRC) is a pharmaceutical company focused on developing
innovative therapeutics to deliver relief from pain and other symptoms in acute and chronic conditions. BRC’s medicines are multimodal and contain cannabinoids at
defined ratios. BRC has developed a pipeline of prescription medicines addressing
neurological and inflammatory conditions. Two investigational products are currently
being tested in clinical trials for Complex Regional Pain Syndrome (CRPS) and
Aromatase Inhibitor-Induced Arthralgia (AIIA), respectively. BRC is registered with the
Drug Enforcement Administration and is based in Monterey, CA.

To learn more about BRC, visit brctherapeutics.com.

Forward‑Looking Statements
This news release contains forward-looking statements within the meaning of Section
27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of
1934 that involve risks, uncertainties and assumptions, including without limitation
statements about the development, use, benefits and effects of Biopharmaceutical
Research Company’s (BRC) therapeutic product candidate and related technology,
future plans for the BRC’s business and growth, expected plans with respect to clinical
trials, including the number of patients enrolled and timing of patient enrollment. In some
cases, you can identify forward-looking statements by terms such as “may,” “will,”
“should,” “expect,” “design,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,”
“contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the
negative of these terms or other similar expressions. Such statements and other
statements in this press release that are not descriptions of historical facts are forward-
looking statements that are based on management’s current expectations and
assumptions and are subject to risks and uncertainties. If such risks or uncertainties
materialize or such assumptions prove incorrect, our business, operating results,
financial condition, and stock price could be materially negatively affected. Actual results
and the timing of events could differ materially from those anticipated in these forward-
looking statements. The forward-looking statements made herein speak only as of the
date of this press release and, unless otherwise required by law, BRC does not
undertake any obligation to publicly update such forward-looking statements to reflect
subsequent events or circumstances.